-
Mashup Score: 72The origin of ferritin reference intervals: a systematic review - 12 month(s) ago
Iron deficiency is a highly prevalent condition, which contributes to unnecessary morbidity, mortality, and health inequity. A serum ferritin concentration of less than 30 μg/L has a high specificity and sensitivity for diagnosing iron deficiency in adults, but the laboratory reported lower limit of normal (LLN) is typically lower. These LLNs might not be rooted in rigorous scientific evidence and might be contributing to structural underdiagnosis of iron deficiency. A systematic review was done per systematic reviews and meta-analysis guidelines with the use of medical literature databases from inception of each database to Nov 30, 2021, to identify studies that determined ferritin reference intervals in healthy adults and grey literature search for the five most common ferritin assays (registration number CRD42022268844).
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Ruxolitinib: a game changer in paediatric chronic graft-versus-host disease management? - 12 month(s) ago
Chronic graft-versus-host disease (GVHD) remains a severe complication after allogeneic haematopoietic stem-cell transplantation, especially in paediatric populations. In The Lancet Haematology, Franco Locatelli and colleagues1 report the interim analysis of the REACH5 study, which addresses a crucial need for effective treatments in this susceptible group, exploring the activity and safety of ruxolitinib (a JAK1/JAK2 inhibitor) in treating paediatric patients (ie, younger than 18 years) with moderate-to-severe chronic GVHD.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
"In the context of current clinical practice, this study reinforces the use of ruxolitinib as a viable option for paediatric chronic GVHD, addressing the need for effective treatments in this population" #bmtsm Commet by Luisa Sisinni https://t.co/7zTzJuDF2G
-
-
Mashup Score: 9
Pending final analysis, this study suggests that ruxolitinib is active and well tolerated in both treatment-naive and corticosteroid-refractory patients aged 2 years to younger than 18 years with chronic GVHD, thereby supporting its use in this patient population. The safety profile of ruxolitinib in this patient population is consistent with that of adults. Final analysis of this study will provide further information on the long-term benefits of ruxolitinib in children with chronic GVHD.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
NEW: an interin analysis of the REACH5 trial shows that ruxolitinib is active & safe in patients with chronic GVHD aged 2 to younger than 18 years, thereby supporting the use of ruxolitinib as first-line or second-line therapy after corticosteroids #bmtsm https://t.co/OKxwJr1E5E https://t.co/6cAMSvI6ks
-
-
Mashup Score: 260Diagnosis and management of Evans syndrome in adults: first consensus recommendations - 1 year(s) ago
Evans syndrome is a rare disease marked by a severe clinical course, high relapse rate, infectious and thrombotic complications, and sometimes fatal outcome. Management is highly heterogeneous. There are several case reports but few large retrospective studies and no prospective or randomised trials. Here, we report the results of the first consensus-based expert recommendations aimed at harmonising the diagnosis and management of Evans syndrome in adults. After reviewing the literature, we used a fuzzy Delphi consensus method, with two rounds of a 42-item questionnaire that were scored by a panel of 13 international experts from five countries using a 7-point Likert scale.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
Evans syndrome is a rare disease marked by a severe clinical course and sometimes fatal outcome. Management is highly heterogeneous. Read the first consensus recommendations for the diagnosis and management of Evans syndrome in adults https://t.co/tQIzCEeL3Y https://t.co/n35C1yRP73
-
-
Mashup Score: 2The evolutionary journey from essential thrombocythaemia to acute erythroid leukaemia - 1 year(s) ago
A 69-year-old woman presented in September, 2023, at Fondazione IRCCS Policlinico San Matteo, Pavia, Italy because of pancytopenia. She had an 11-year history of JAK2 V617F-mutated (variant allele frequency [VAF] 32%) essential thrombocythaemia treated with hydroxyurea. Cytogenetics at diagnosis was normal. At the time of admission, laboratory data showed leukopenia (leukocytes 1·83 × 109 cells per L), anaemia (haemoglobin 63 g/L), thrombocytopenia (platelets 112 × 109 platelets per L), and increased lactate dehydrogenase (1021 mU/mL).
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
Thanks for taking part. The correct answer is option 2, acute erythroid leukaemia. The full clinical picture can be read here: https://t.co/SZ87xt5CJt
-
-
Mashup Score: 15
The combination of iadademstat and azacitidine has a manageable safety profile and shows promising responses in patients with newly diagnosed acute myeloid leukaemia, including those with high-risk prognostic factors.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet-
NEW: Iadademstat in combination with azacitidine has a manageable safety profile and shows promising responses in patients with newly diagnosed acute myeloid leukaemia in the phase 2a ALICE trial #leusm https://t.co/6VU7Co7405 https://t.co/G3MoQFILSM
-
-
Mashup Score: 29Obiageli Nnodu: sickle cell disease in Africa's largest nation - 1 year(s) ago
With a current population quickly approaching 230 million, Nigeria is Africa’s largest nation and has the world’s highest incidence of sickle cell disease. Each year, about 150 000 Nigerian children are born with the condition. For a long time, the country did not have a well articulated plan to contend with sickle cell disease. But this changed about 14 years ago when Obiageli Nnodu was invited to help articulate a strategy for the control and management of the disease. Preparing for this endeavour led her to the First Global Congress on Sickle Cell Disease in Accra, Ghana, in 2010 where she observed a lack of coordination and communication among various individuals and non-governmental organisations involved with sickle cell disease in Nigeria.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
Nigeria has Africa's largest population & the world's highest incidence of #sicklecell disease Read about Obiageli Nnodu, who has endeavoured to integrate newborn screening into existing healthcare🇳🇬 @SickleInAfrica https://t.co/XSTPIsvfrD
-
-
Mashup Score: 90Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial - 1 year(s) ago
Most patients had a complete response after 4 Gy radiotherapy; all who required an additional 20 Gy had a complete response within 12 months. This response-adapted strategy could be used to select patients who would benefit from additional radiotherapy and spare others potential associated toxicity.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet-
NEW: Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT #lymphoma: a single-centre, pilot trial @MDAndersonNews #lymsm https://t.co/1JhqQ81NfM
-
-
Mashup Score: 21
Combination treatment of low-dose, single-fraction radiotherapy with pembrolizumab was safe, with early promise of response activity. Our approach could be an option for patients with relapsed or refractory multiple myeloma who have not responded to previous treatment. Larger trials to substantiate our findings are needed.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet-
NEW: a pilot, phase 2 trial showed pembrolizumab and low-dose, single-fraction radiotherapy was safe, with early promise of response activity in patients with relapsed or refractory multiple myeloma #radonc #mmsm https://t.co/yhTlzn6e9z https://t.co/r8D5ucgD4k
-
-
Mashup Score: 0
Local radiotherapy is frequently not associated with the eradication of follicular lymphoma. An MRD-driven, anti-CD20 monoclonal antibody consolidation enables molecular remission to be reached in almost all patients and is associated with a reduced incidence of relapse over time. A clinical advantage of an MRD-driven consolidation is therefore suggested.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
(1) MRD-driven therapy after radiotherapy for early-stage follicular lymphoma enables molecular remission in almost all patients and is associated with reduced relapse: results of the phase 2 Fondazione Italiana Linfomi-MIRO trial #lymsm https://t.co/LL6cpjlebO https://t.co/b97jGbLCDG
-
"Ferritin reference intervals are at high risk of bias" #anaemia #irondeficiency ICYMI: The origin of ferritin reference intervals: a systematic review https://t.co/JsDwnJ9ey8 https://t.co/Z36x9jLcOl